The cost-effectiveness of navelbine alone or in combination with cisplatin in comparison to other chemotherapy regimens and best supportive care in stage IV non-small cell lung cancer

European Journal of Cancer Part A

Volumn 32, Issue 13, 1996, Pages 2249-2255

  Evans, W K ^b   Le Chevalier, T ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b NONE

Author keywords

Chemotherapy; Cisplatin; Cost; Lung cancer; Navelbine

Indexed keywords

CISPLATIN; ETOPOSIDE; NAVELBINE; VINBLASTINE; VINDESINE;

ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEALTH CARE COST; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG CANCER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COST-BENEFIT ANALYSIS; DRUG COSTS; HEALTH CARE COSTS; HUMANS; LUNG NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; SURVIVAL RATE; VINBLASTINE;

EID: 0030446760     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00298-5     Document Type: Article

References (23)

1. 1. Le Chevalier T, Brisgand D, Douillard JY, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer: results of European multicenter trial including 612 patients. J Clin Oncol 1994, 12, 360-367.
2. 2. Le Chevalier T, Pujol JL, Douillard JY, et al. A three-arm trial of vinorelbine (Navelbine) plus cisplatin, vindesine plus cisplatin, and single-agent vinorelbine in the treatment of non-small cell lung cancer: an expanded analysis. Semin Oncol 1994, 21(Suppl. 10), 28-34.
3. 3. Evans WK, Will BP, Berthelot J-M, Wolfson MC. Diagnostic and therapeutic approaches to lung cancer in Canada and their costs. Br J Cancer 1995, 72, 1270-1277.
4. 4. Evans WK, Will BP, Berthelot J-M, Wolfson MC. Estimating the cost of lung cancer diagnosis and treatment in Canada: the POHEM model. Can J Oncol 1995, 5, 408-419.
5. 5. Wolfson MC. POHEM - A framework for understanding and modelling the health of human populations. Presented at Bureau of Census 1992 Annual Research Conference, Arlington Virginia. In Proc Ann Res Conf 1992, 261-282.
6. 6. Rapp E, Pater JL, Willan A, et al. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer - report of a Canadian multicenter randomized trial. J Clin Oncol 1988, 6, 633-641.
7. 7. Jaakkimainen L, Goodwin PJ, Pater J, et al. Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in non-small-cell lung cancer. J Clin Oncol 1990, 8, 1301-1309.
8. 8. Dhingra HM, Valdivieso M, Carr DT, et al. Randomized trial of three combinations of cisplatin with vindesine and/or VP-16 in the treatment of advanced non-small cell lung cancer. J Clin Oncol 1985, 3, 176-183.
9. 9. Ruckdeschel JC, Finkelstein DM, Ettinger DS, et al. A randomized trial of the four most active regimens for metastatic non-small cell lung cancer. J Clin Oncol 1986, 4, 14-22.
10. 10. Grilli R, Oxman AD, Julian JA. Chemotherapy for advanced non-small cell lung cancer: how much benefit is enough? J Clin Oncol 1993, 11, 1866-1872.
11. 11. Souquet PJ, Chauvin F, Boissel JP, et al. Polychemotherapy in non-small cell lung cancer: a meta-analysis using updated individual patient data from 52 randomized clinical trials. Lancet 1993, 342, 19-21.
12. 12. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated individual patient data from 52 clinical trials. Br Med J 1995, 311, 899-909.
13. 13. Osoba D, Rusthoven JJ, Turnbull KA, et al. Combination chemotherapy with bleomycin, etoposide and cisplatin in metastatic non-small cell lung cancer. J Clin Oncol 1985, 3, 1478-1485.
14. 14. Fernandez C, Rosell R, Abad-Esteve A, et al. Quality of life during chemotherapy in non-small cell lung cancer patients. Acta Oncol 1989, 28, 129-133.
15. 15. Ellis PA, Smith IE, Hardy JR, et al. Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer. Br J Cancer 1995, 71, 366-370.
16. 16. Kris MG, Gralla RJ, Potanovich LM, et al. Assessment of pretreatment symptoms and improvement after EDAM mitomycin vinblastine (EMV) in patients with inoperable non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1990, 9, 229, 883 (abstract).
17. 17. Raby B, Pater J, MacKillop WJ. Does knowledge guide practice? Another look at the management of non-small cell lung cancer. J Clin Oncol 1995, 13, 1904-1911.
18. 18. Smith TJ, Hillner BE, Neighbours DM, et al. Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small cell lung cancer. J Clin Oncol 1995, 13, 2166-2173.
19. 19. Laupacis A, Feeney D, Detsky AS, Tugwell P. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc 1992, 146, 473-481.
20. 20. Shulman KA, Lynn LA, Glick HA, Eisenberg JM. Cost-effectiveness of low-dose zidovudine therapy for asymptomatic patients with human immunodeficiency virus (HIV). Ann Int Med 1991, 114, 798-802.
21. 21. Tengs TO, Adams ME, Pliskin JS, et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Analysis 1995, 15, 369-390.
22. 22. Ganz PA, Figlin RA, Haskell CM, et al. Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer. Does chemotherapy make a difference? Cancer 1989, 63, 1271-1278.
23. 23. Feld R. Quality of life in patients with non-small cell lung cancer treated with chemotherapy. Eur J Cancer Clin Oncol 1987, 3, 357-359.